ArdelyxMEX:ARDX 69 EV-to-FCF is -31.27 as of Jul. 02, 2026. GuruFocus rates MEX:ARDX with a GF Score™ of 69/100 and a GF Value™ of MXN195.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 333 Biotechnology companies, Ardelyx ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ardelyx's Enterprise Value is MXN21,809 Mil.
Ardelyx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-697 Mil. Therefore, Ardelyx's EV-to-FCF for today is -31.27.
The historical rank and industry rank for Ardelyx's EV-to-FCF or its related term are showing as below:
MEX:ARDX'
s EV-to-FCF Range Over the Past 10 Years
Min: -44.31 Med: -4.06 Max: 0.7
Current: -33.26
During the past 13 years, the highest EV-to-FCF of Ardelyx was 0.70. The lowest was -44.31. And the median was -4.06.
MEX:ARDX's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs MEX:ARDX: -33.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-02), Ardelyx's stock price is MXN99.00.
Ardelyx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-4.188. Therefore, Ardelyx's PE Ratio (TTM) for today is At Loss.
Ardelyx (MEX:ARDX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ardelyx's share price for today is MXN99.00.
Ardelyx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4.188.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ardelyx EV-to-FCF Related Terms
Ardelyx EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ardelyx's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ARDX vs AVLN, INBX, JBIO: EV-to-FCF Comparison
For the Biotechnology subindustry, Ardelyx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ardelyx's EV-to-FCF falls into.
Ardelyx's current Enterprise Value is MXN21,809 Mil.
Ardelyx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-697 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (MEX:ARDX) has a EV-to-FCF of -31.27 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #999999 out of 333 companies in the Biotechnology industry.
Is Ardelyx's EV-to-FCF too high?
Ardelyx's current EV-to-FCF is -31.27. Based on the distribution chart, Ardelyx ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ardelyx has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's EV-to-FCF compare to AVLN and INBX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #999999 out of 333 companies for EV-to-FCF. This places Ardelyx in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ardelyx and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ardelyx's current EV-to-FCF is -31.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (MEX:ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN195.32, compared to a current price of MXN99.00 — trading 49.3% below its estimated fair value. The current EV-to-FCF is -31.27. Ardelyx's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ardelyx (MEX:ARDX), the current EV-to-FCF is -31.27 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (MEX:ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of MXN99.00 is trading 49.3% below its estimated GF Value™ of MXN195.32.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for MEX:ARDX:
EV-to-FCF: -31.27
GF Value™: MXN195.32 vs. price of MXN99.00 (49.3% below fair value)
No single metric tells the full story. See the MEX:ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
69GF Score
Get the complete analysis for MEX:ARDX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ARDX has been successfully added to your 
